secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001437749-26-006209
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton Pharma acquires U.S. rights to HEMANGEOL for $14M upfront
--------------------------------------------------------------

- Eton pays $14M upfront plus 8% royalty; $1.5M inventory at close and $0.7M in May 2026.
- HEMANGEOL is the only FDA-approved treatment for proliferating infantile hemangioma; 2025 sales $11.7M.
- Deal financed with cash on hand; expected to be accretive to 2026 earnings.
- Pierre Fabre distributes until April 30; Eton commercializes from May 1 via Eton Cares program.
- Acquisition gives Eton ten commercial rare-disease products, including recent DESMODA approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774926006209/0001437749-26-006209-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774926006209/eton20260223c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-006209

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer